Elevated high sensitivity C-reactive protein levels in aging men with low testosterone

References

• Kaplan SA, Meehan AG, Shah A. The age-related decline in testosterone is significantly exacerbated in obese men with the metabolic syndrome – what are the implications of this for the relatively high incidence of erectile dysfunction observed in these men? J Urol 2006;176:1524–1528.
   PubMed Web of Science ®Google Scholar
• Matsumoto AM. Andropause: clinical implications of the decline in serum testosterone levels with aging in men. J Gerontol 2002;57A:M76–M99.
   Google Scholar
• Laaksonen DE, Niskanen L, Punnonen K, Nyyssonen K, Tuomainen TP, Salonen R, Rauramaa R, Salonen JT. Sex hormones, inflammation and the metabolic syndrome: a population-based study. Eur J Endocrinol 2003;149:601–608.
   PubMed Web of Science ®Google Scholar
• Laaksonen DE, Niskanen L, Punnonen K, Nyyssönen K, Tuomainen T-P, Valkonen V-P, Salonen R, Salonen JT. Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care 2004;27:1036–1041.
   PubMed Web of Science ®Google Scholar
• Laaksonen DE, Niskanen L, Punnonen K, Nyyssönen K, Tuomainen T-P, Valkonen V-P, Salonen JT. The metabolic syndrome and smoking in relation to hypogonadism in middle-aged men: a prospective cohort study. J Clin Endocrinol Metab 2005;90:712–719.
   PubMed Web of Science ®Google Scholar
• Pitteloud N, Mootha VK, Dwyer AA, Hardin M, Lee H, Eriksson K-F, Tripathy D, Yialamas M, Groop L, Elahi D, Hayes FJ. Relationship between testosterone levels, insulin sensitivity, and mitochondrial function in men. Diabetes Care 2005;28:1636–1642.
   PubMed Web of Science ®Google Scholar
• Dhindsa S, Prabhakar S, Sethi M, Bandyopadhyay A, Chaudhuri A, Dandona P. Frequent occurrence of hypogonadotropic hypogonadism in type 2 diabetics. J Clin Endocrinol Metab 2004;89:5462–5468.
   PubMed Web of Science ®Google Scholar
• Bhatia V, Chaudhuri A, Tomar R, Dhindsa S, Ghanim H, Dandona P. Low testosterone and high C-reactive protein concentrations predict low hematocrit in type 2 diabetes. Diabetes Care 2006;29:2289–2294.
   PubMed Web of Science ®Google Scholar
• Nakhai Pour HR, Grobbee DE, Muller M, van der Schouw YT. Association of endogenous sex hormone with C-reactive protein levels in middle-aged and elderly men. Clin Endocrinol 2007;66:394–398.
   Google Scholar
• Maggio M, Basaria S, Ble A, Lauretani F, Bandinelli S, Ceda GP, Valenti G, Ling SM, Ferrucci L. Correlation between testosterone and the inflammatory marker soluble interleukin-6 receptor in older men. J Clin Endocrinol Metab 2006;91:345–347.
   PubMed Web of Science ®Google Scholar
• Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO, Criqui M, Fadl YY, Fortmann SP, Hong Y, Myers GL, Rifai N, Smith SC, Taubert K, Tracy RP, Vinicor F. Markers of inflammation and cardiovascular disease: application to clinical and public health practice. A statement for healthcare professionals from the Centers for Disease Control and prevention and the American Heart Association. Circulation 2003;107:499–511.
   PubMed Web of Science ®Google Scholar
• Metropolitan Life Insurance Company. 1983. Metropolitan height and weight tables. Stat Bull 1983;64:2–9.
   Google Scholar
• Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486–2497.
   PubMed Web of Science ®Google Scholar
• Zuliani G, Volpato S, Galvani M, Blè A, Bandinelli S, Corsi AM, Lauretani F, Maggio M, Guralnik JM, Fellin R, Ferrucci L. Elevated C-reactive protein levels and metabolic syndrome in the elderly: the role of central obesity: data from the InChianti study. Atherosclerosis 2009;203:626–632.
   PubMed Web of Science ®Google Scholar
• Ding EL, Song Y, Malik VS, Liu S. Sex differences of endogenous sex hormones and risk of type diabetes: a systematic review and meta-analysis. JAMA 2006;295:1288–1299.
   PubMed Web of Science ®Google Scholar
• Vertkin AL, Naumov AV, Morgunov LY, Kalinchenko SY, Krivtsova EV, Arinina EN, Kolosova ES, Plupanova YS. Testosterone effects on cardiovascular risk factors in men with metabolic syndrome. Cardiovasc Ther Prev 2008;7:68–75.
   Google Scholar
• Giltay EJ, Haider A, Saad F, Gooren LJ. C-reactive protein levels and ageing male symptoms in hypogonadal men treated with testosterone supplementation. Andrologia 2008;40:398–400.
   PubMed Web of Science ®Google Scholar
• Haider A, Gooren LJ, Padungtod P, Saad F. Concurrent improvement of the metabolic syndrome and lower urinary tract symptoms upon normalisation of plasma testosterone levels in hypogonadal elderly men. Andrologia 2009;41:7–13.
   PubMed Web of Science ®Google Scholar
• Malkin CJ, Pugh PJ, Jones RD, Kapoor D, Channer KS, Jones TH. The effect of testosterone replacement on endogenous inflammatory cytokines and lipid profiles in hypogonadal men. J Clin Endocrinol Metab 2004;89:3313–3318.
   PubMed Web of Science ®Google Scholar
• Mauduit C, Gasnier F, Rey C, Chauvin M-A, Stocco DM, Louisot P, Benahmed M. TNF alfa inhibits leydig cell steroidogenesis through a decrease in steroidogenic acute regulatory protein expression. Endocrinology 1998;139:2863–2868.
   PubMedGoogle Scholar
• Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults. JAMA 2002;287:356–359.
   PubMed Web of Science ®Google Scholar